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OBJECTIVES: To determine the annual direct medical cost of the management of
adult patient with active antinuclear autoantibody positive SLE. METHODS: LUCIE
is a multicenter, observational, retrospective study carried out in five European
countries, including France. SLE patients characteristics, disease severity (severe
patient defined as having at least one major domain actively involved at inclusion:
renal, neurological, cardiovascular or respiratory AND Requiring corticosteroids 
7.5 mg/day and/or immunosuppressants), flares rate, health care consumption
(laboratory tests, biopsies and/or imaging tests, medications, specialist visit, hos-
pitalisations) were collected retrospectively over a two-years period. The French
national health insurance perspective was considered when estimating the aver-
age annual direct cost using official cost database. Major cost drivers associated
with SLE and flares management were identified by multivariate regression
models. RESULTS: Eight French SLE centres participated in the study, and included
96 consecutive patients: mean age 39.911.9 years, 93.5% females. The mean SLE
duration was 9.86.6 years, the mean SELENA-SLEDAI score, a semiquantitative
index of SLE activity was 7.75.1. On average, SLE patients had 1.10.59 flares/year.
The annual unadjusted mean direct medical cost of SLE patients was €4116
(SD5498). In severe patients the cost was 1.3 times higher: €4660 versus €3560 in
non-severe patients (NS). Medical treatment represents the largest component of
the average annual direct cost of SLE patients (61.8%) and was higher in severe
patients (7214€ versus 1855€, p0.030). Biological drugs, even though prescribed to
only 10.8% of patients, represented 3.4% of the annual total medical treatment cost.
The multivariate regression model showed that each severe flare increases cost by
€1230 (p0.2). CONCLUSIONS: The annual direct medical cost of active SLE is sig-
nificant especially for patients experiencing severe flare and is mostly driven by the
cost of medication.
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OBJECTIVES: Medication adherence and persistence are important in the treat-
ment of fibromyalgia. The objective of this study is to examine the predictors of
adherence and persistence to duloxetine therapy among commercially-insured
fibromyalgia patients. METHODS: This study analyzed medical and pharmacy re-
cords for commercially-insured patients aged 18-64 with fibromyalgia who initi-
ated (no prior 90-day use) duloxetine in 2008. Patients selected had continuous
health insurance enrollment for 12 months preceding and following duloxetine
initiation, at least 1 fibromyalgia diagnosis during the 12 months before, or 1 month
after, the initiation date, and at least 30-day cumulative duloxetine supply over the
12-month post-index period. Adherence to duloxetine was measured by medica-
tion possession ratio (MPR  post 1-year total duloxetine supply days/365), with
high adherence defined as MPR 0.8. Persistence was defined as the length of
therapy (LOT) from the index date to the earliest of the ending date of the last
prescription, the date of the first gap of more than 15 days between prescriptions,
or the end of study period (12 months). Demographic and clinical predictors of
adherence and persistence were examined via multivariate logistic regression
(MLR) and classification and regression trees (CART). RESULTS: Among 4,660 du-
loxetine patients, 33% achieved high adherence. Factors associated with high ad-
herence from MLR included older age, North Central and Northeast regions, prior
venlafaxine, pregabalin, SSRIs or other antidepressants use, or comoribid dyslipi-
demia, osteoarthritis, or skin and subcutaneous tissue disorders (all p0.05). CART
analysis revealed that patients with prior use of antidepressants, age 46, or prior
osteoarthritis disorder had higher MPR (all p0.05), and patients aged 45 with a
history of SSRI, venlafaxine or anticonvulsant use had longer LOT (all p0.05).
CONCLUSIONS: One-third of fibromyalgia patients on duloxetine achieved high
adherence. Patients with high adherence and persistence to duloxetine were sig-
nificantly older and had prior antidepressant use.
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OBJECTIVES: To compare the costs of adding pregabalin or gabapentin to existing
therapy in patients with peripheral neuropathic pain (PNeP) in routine medical
practice in a Spanish setting. METHODS: A retrospective database analysis was
performed using patients’ medical claims records. Medical records from male and
female patients, with PNeP, 18 years, in whom pregabalin, or gabapentin was
initiated between 2006 and 2008 were included in the analysis. The economic
model included health care resource utilization and corresponding costs, from a
third-payer perspective. Estimates of indirect costs, due to sick leave were
included. RESULTS: A total of 1160 records were eligible for analysis: 764 (65.7%)
treated with pregabalin and 399 (34.3%) gabapentin. Patients in both groups were
comparable. No significant differences were observed for previous average number
of analgesics: pregabalin 2.7 (0.1); gabapentin 2.8 (0.1), p0.362. However, concom-
itant use of analgesics was higher in gabapentin cohort; 3.2 (0.1) versus 2.7 (0.1);
p0.003, mainly due to a higher utilization of NSAIDs (74.9% versus 69.5%; p0.018)
and opioids (27.7% vs. 17.9%; p0.031). Adjusted mean (95% CI) total costs per
patient were significantly lower in pregabalin group; €2514 (2228-2800) versus €3241
(2853-3630); p 0.003, due to minor labour productivity losses; €1067 (790-1345)
versus €1633 (1256-2009); p0.018, and lower adjusted health care costs; €1447
(1380-1513) versus €1609 (1519-1698); p0.004. The higher drug acquisition costs for
pregabalin [€351 versus €191; p0.001) was compensated for by lower overall
health care costs, mainly in medical visits, physiotherapy, hospitalization days and
concomitant analgesics. CONCLUSIONS: In a population setting in Spain, pregaba-
lin treated patients with PNeP were considerable less costly for the healthcare
provider than those treated with gabapentin in routine clinical practice. The higher
acquisition cost of pregabalin was compensated largely by lower costs in the other
components of health care costs. Patients treated with pregabalin had significantly
less sick leaves than gabapentin treated patients.
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OBJECTIVES: Adding pregabalin or gabapentin to existing therapy in patients with
painful radiculopathies in routine medical practice in a Spanish health care setting.
METHODS: A retrospective database analysis was performed using patients’ med-
ical claims records from BSA. Medical records from male and female, with cervical,
dorsal or lumbar painful radiculopathy, 18 years, in whom pregabalin, or gabap-
entin was initiated between 2006 and 2008 were included in the analysis. The
economic analysis included healthcare resource utilization and corresponding
costs from a third-payer perspective. Estimates of indirect costs, due to sick leave
were also included. RESULTS: A total of 571 records were eligible for analysis: 378
(66.2%) treated with pregabalin and 193 (33.8%) gabapentin. Time since diagnosis,
duration of treatment, prevalence of most comorbidities and previous use of anal-
gesics were comparable. However, concomitant use of analgesics was higher in
gabapentin cohort; 3.1 (1.7) versus 2.8 (1.8); p0.05, mainly due to a higher utiliza-
tion of opioids (31.1% vs. 21.2%; p0.05) and non-narcotic (63.7% vs. 52.1%; p0.01)
drugs. Adjusted total costs per patient were significantly lower in pregabalin group;
€2472 (2101-2836) versus. €3346 (2866-3825); p 0.005, due to minor absenteeism
costs; €1012 (658-1365) versus €1595 (1129-2062); p0.042, and lower adjusted
health care costs; €1,460 (1,360-1,560) versus €1750 (1618-1882); p0.001. The higher
drug acquisition costs for pregabalin [€343 vs. €222; p0.001) was largely compen-
sated for by lower overall health care costs, mainly in primary care medical visits,
hospitalization days and concomitant analgesics. CONCLUSIONS: In a population
setting in Spain, pregabalin treated patients with painful radiculopathies were
considerable less costly for the health care provider than those treated with gaba-
pentin in routine clinical practice. The higher acquisition cost of pregabalin was
compensated largely by lower costs in the other components of health care costs.
Patients treated with pregabalin had significantly less sick leaves than gabapentin
treated patients.
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OBJECTIVES: In recent years there has been a large increase in the number of
morbidly obese persons subject to hospital surgery. In Portugal, 14% of the popu-
lation of working age is obese. As in other countries these numbers have been
rising and it is well known that obese individuals have an increased risk of mor-
bidity and premature death from various diseases. We estimate the impact of
obesity on the health sector by calculating the costs of hospital inpatient care
associated with obesity in Portugal. METHODS: A prevalence-based cost of treat-
ment approach is adopted. Hospital episode micro data are drawn from the Na-
tional Health Service’s (NHS) DRG information system for 2008 (n965 212). Besides
episodes where the main diagnosis is obesity, population attributable fractions are
calculated for 16 co-morbidities (CID-9-MC), including diabetes type 2, musculosk-
eletal diseases, cardiovascular conditions and some types of cancer. Relative risks
are drawn from a recent meta-analysis of large-scale prospective studies and prev-
alence data from a nationally representative examination survey that recorded
anthropometric data. Unit cost data are taken from an NHS database. RESULTS:
The hospital inpatient costs of obesity in NHS hospitals in 2008 are estimated as €
85.9 million. This corresponds to 0.92% of annual NHS expenditure. The three
major contributors to this total are osteoarthritis (19.9%), obesity (15.4%) and isch-
emic heart disease (14.7%). If circulatory and cerebrovascular system diagnoses are
grouped together, they become the largest contributors to total costs.
CONCLUSIONS: The structure of costs by diagnosis is different to that commonly
found in ambulatory care. Despite the sharp increase in the number of persons
subject to obesity surgery the overall inpatient care costs have remained largely
stable over time. There has been a large increase in the resources used to treat
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obesity directly, but a corresponding decrease in resources used to treat co-mor-
bidities.
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OBJECTIVES: Obesity has reached epidemic proportions and has many cost impli-
cations. Being overweight and obese is associated with higher rates of many
chronic health conditions, which in turn leads to increases in medical spending
and productivity losses. Many worksites have implemented weight management
programs for employees to offset the cost burden of disease. This study modeled
the potential cost savings for an employer from a 2-year worksite weight manage-
ment program over ten year time horizon. METHODS: We used data from a group
randomized control trial of a worksite weight management program and published
healthcare utilization data to model long term net costs. Using a Markov decision
analytic modeling technique, we conducted a cost benefit analysis of weight man-
agement program versus usual practice. Program costs, health care utilization and
prevalence of overweight and obesity in the study population were used to assess
program impact. Sensitivity analyses were conducted to find a threshold at which
the intervention would have a positive net benefit. RESULTS: The study population
showed had a 1.44% decrease in the overweight/obesity in one year. When modeled
over 10 years, this program incurred an excess cost of $206 per person compared to
usual practice. The threshold at which this program would have a positive net
benefit is when there is a 5.8% decrease in the overweight/obese population
annually. CONCLUSIONS: Worksite weight management programs may yield cost
savings with modest reduction in the percentage of overweight or obese employ-
ees. This evidence may encourage employers to implement and support weight
management programs that have empirically demonstrated higher rates of weight
loss in employees. More research is needed to understand why some individuals
are more successful at weight reduction and to evaluate long-term effectiveness of
weight management at worksites.
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OBJECTIVES: Romiplostim stimulates platelet production via the thrombopoetin-
receptor and is recommended for second- and third-line treatment of chronic ITP
in adults. Traditional treatment options in this setting have included unapproved
use of the immunosuppressant rituximab. This analysis assessed the cost per re-
sponder of romiplostim compared to rituximab in adult ITP patients in France.
METHODS: A decision analytic model was developed to estimate the six-month
cost per patient responding to treatment. A systematic literature review was per-
formed to obtain response rates (achieving a platelet count 50x109/L) for each
treatment. Romiplostim patients received weekly administrations; rituximab pa-
tients received 4 weekly intravenous infusions. Resource utilization was based on
French and international treatment guidelines, and clinical expert opinion. Unit
costs were derived from published literature and French reimbursement lists, and
included the costs of routine physician visits, treatment administration and emer-
gency care. Non-responders incurred the cost of rescue therapy (IVIg and predni-
sone) and hospitalizations/physician visits associated with bleeding-related
events (BREs). RESULTS:Although the comparability of existing literature for romi-
plostim and rituximab was limited, several fulfilled the literature review selection
criteria. Response rates were 83% and 62.5%, as per the romiplostim pivotal trial
and a meta-analysis on rituximab, respectively. Mean cost per patient for romi-
plostim and rituximab was €17,486 and €17,086 respectively. Dividing mean cost
per patient by response rates, cost per response was €27,337 for romiplostim and
€25,178 for rituximab. The main cost-offsets were due to reduced rescue therapy
and BREs, with romiplostim resulting in a 23% reduction in cost per platelet re-
sponse. Across sensitivity analyses, romiplostim consistently produced a lower
cost per response.CONCLUSIONS: In adult ITP patients, romiplostim yields a lower
cost per response over 6 months compared to rituximab, indicating romiplostim
represents an efficient use of resources for the French health care system.
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OBJECTIVES: Continuous wound infiltration (CWI), intravenous patient controlled
analgesia (iv-PCA) and epidural analgesia (EDA) are analgesic techniques com-
monly used for pain relief after open abdominal surgery. The aim of this study was
to evaluate the cost-impact and cost-effectiveness of these analgesic techniques.
METHODS: A decision tree model was developed in which patients entered after
successful colorectal surgery and received post-operative analgesia. The pathways
consist of a number of particular events including patient eligibility given their
agreement to benefit from the technique, rate of intra-operative technical failure,
successful pain relief and potential adverse events. Data was retrieved from clini-
cal trials and from an observational prospective cohort of 85 patients. Efficacy
criteria were based on pain at mobilisation. Healthcare resource use and costs were
evaluated from medical records measurements and published data. The incremen-
tal cost-effectiveness ratio (ICER) was expressed as the ratio between differential
total cost of procedures and differential efficacy. Probabilistic sensitivity analysis
(PSA) was performed around the willingness to pay per controlled patient.
RESULTS: When taking into account all the healthcare resources consumed, the
CWI arm (€4,044) is economically dominant compared to iv-PCA (€4,779). EDA is
more costly, but also more effective than CWI, with an estimated ICER of €27,446 for
each additional controlled patient. PSA analysis shows that CWI remains cost-
saving in 71.3% of cases. CONCLUSIONS:Device-related costs of using CWI for pain
management after abdominal laparotomy are partly counterbalanced by a reduc-
tion in healthcare resource consumption. It is also important to consider that a
proportion of patients do not have the capacity to benefit from epidural techniques
and some may also refuse the technique. This economic evaluation may be useful
for clinicians to design algorithms for pain management after major abdominal
surgery.
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OBJECTIVES: About 5% of the population (400,000 in Austria) suffer from neuro-
pathic pain. Fifty percent of them denominate their pain as “very strong”. Neuro-
pathic pain patients consult on average 5 different doctors before the main diag-
nosis is found. The aim of this study was to evaluate the cost-effectiveness of
treatment of neuropathic pain with topical Capsaicin Patch 8% versus current stan-
dard of care (pregabalin) in Austria. METHODS: The analysis was performed using
a Decision Tree Model combined with a Markov model adapted for Austria. The
model is based on an indirect comparison, which results in a conservative estima-
tion, as the efficacy of capsaicin patch 8% is underestimated due to a large placebo
effect. Efficacy assessment was based on the outcome measure QALY. Costs were
captured for the year 2011. Resource use was determined by literature research and
expert opinion and accurately reflects the Austrian treatment path. The study time
horizon was 5 years. The analysis was performed from the perspective of social
health insurance. The analysis was conducted according to Austrian Guidelines for
Health Economic Evaluations. RESULTS: The results are shown for a time horizon
of 5 years. The cost per patient (30% pain reduction) for capsaicin patch 8% amount
to €4898 for a time horizon of 5 years and to €4745 for Pregabalin. Treatment with
capsaicin patch 8% leads to 3.011 QALYs, treatment with Pregabalin to 2.964 QALYs.
The cost per QALY is €1627 (capsaicin patch 8%) versus €1611 (Pregabalin) with an
ICER of €2358. CONCLUSIONS: In Austria, the treatment of neuropathic pain with
Capsaicin Patch 8% is a cost-effective alternative compared to Pregabalin from the
perspective of the social health insurance.
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OBJECTIVES: Postoperative pain is one of the main adverse outcomes causing dis-
tress to patients after cesarean delivery. Meanwhile the main analgesic drugs are
opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), more over side effects
such as nausea, vomiting, sedation were reported with opioids. METHODS: This
study was undertaken based on our clinical trial that evaluated postoperative pain
in a double-blinded, randomized, single-dose comparison of Tramadol IM injec-
tion, 100 mg (Group T) and Diclophenac suppository, 100 mg (Group D) given alone-
single dose in 100 patients who had elective cesarean delivery. All patients were
assessed at 0, 6, 12 and 24 hours post operation for pain degree (by Visual Analogue
Score: VAS 1-10), nausea and vomiting. Our outcomes were the reduction in pain.
For the cost estimates of therapeutic schemes, we computed the direct costs of the
analgesics (unitary cost) and disposable material (needles, syringes, padcol). Cost-
Effectiveness Ratio was calculated. RESULTS: The efficacy of Tramadol and Diclo-
phenac were not different significantly (P0.06). Nausea and vomiting were mini-
mal with all treatments. Total costs in T group were $52.38 and in D group were
$161.90. Cost-Effectiveness Ratio of Tramadol to Diclophenac was 2.76.
CONCLUSIONS: Cost-Effectiveness Ratio showed that the cost of Tramadol in this
study was 2.76 times more than Diclophenac with the same efficacy, thus the
analgesic effect of Diclophenac is more cost-effective than Tramadol.
PSY31
COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) COMPARED
TO OXYCODONE CONTROLLED RELEASE (CR) IN PATIENTS WITH CHRONIC
SEVERE NON-CANCER PAIN IN IRELAND
Obradovic M1, Ikenberg R2, Hertel N3, Liedgens H1
1Grünenthal GmbH, Aachen, Germany, 2IMS Health GmbH Und Co. Ohg, Nürnberg, Germany,
3IMS Health, London, UK
OBJECTIVES: To assess the cost effectiveness of tapentadol PR compared with
oxycodone CR for the treatment of patients with chronic severe non-cancer pain in
Ireland.METHODS:A Markov model was developed to assess the costs and benefits
of tapentadol PR and oxycodone CR treatment over a 1 year time horizon from the
Health Service Executive perspective (GMS and DP/LTI Scheme). Patients tolerating
the treatment or having mild adverse events remained on tapentadol or oxy-
codone. Patients who were lacking efficacy or had poor tolerability switched to
either transdermal fentanyl or morphine. 3rd line therapy was defined as absorb-
ing state. Data regarding efficacy, tolerability and utility values (EQ-5D) were de-
A415V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
